EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

The Role of Rho Kinase Inhibitors in Corneal Diseases

Stefan Futterknecht iD, Eleftherios Chatzimichail, Konstantin Gugleta, Georgios D Panos iD, Zisis Gatzioufas

Drug Design, Development and Therapy · 2024-01 · Volume 18 · 97-108

DOI: 10.2147/dddt.s435522 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2024-01. Verfasst von Stefan Futterknecht und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Hospital of Basel, Basel, Switzerland. Hauptthemen laut MEDLINE: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine, Amides, Benzoates, beta-Alanine. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAmidesBenzoatesbeta-AlanineCorneal DiseasesIsoquinolinesPyridinesrho-Associated KinasesSulfonamidesAnimalsHumansEndothelial Cells

Stichwörter der Autor:innen

Fuchs’ endothelial corneal dystrophycorneacorneal diseasescorneal dystrophiescorneal transplantationrho kinase inhibitors

Substanzen

1-(5-Isoquinolinesulfonyl)-2-MethylpiperazineAmidesBenzoatesbeta-AlaninefasudilIsoquinolinesK-115netarsudilPyridinesrho-Associated Kinases

Autor:innen und Institutionen

  • Department of Ophthalmology, University Hospital of Basel, Basel, Switzerland.
  • Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.
  • Department of Ophthalmology, School of Medicine, University of Basel, Basel, Switzerland.
  • Department of Ophthalmology, Queen's Medical Centre, Nottingham University Hospitals, Nottingham, UK.
  • Division of Ophthalmology and Visual Sciences, School of Medicine, University of Nottingham, Nottingham, UK.

ORCID-Profile: Stefan Futterknecht, Georgios D Panos

Zitieren

APA

Futterknecht, S., Chatzimichail, E., Gugleta, K., Panos, G. D., & Gatzioufas, Z. (2024). The Role of Rho Kinase Inhibitors in Corneal Diseases. Drug Design, Development and Therapy, Volume 18, 97-108. https://doi.org/10.2147/dddt.s435522

Vancouver

Futterknecht S, Chatzimichail E, Gugleta K, Panos GD, Gatzioufas Z. The Role of Rho Kinase Inhibitors in Corneal Diseases. Drug Design, Development and Therapy. 2024;Volume 18:97-108. doi:10.2147/dddt.s435522

BibTeX
@article{Futterknecht2024,
  author = {Futterknecht, Stefan and Chatzimichail, Eleftherios and Gugleta, Konstantin and Panos, Georgios D and Gatzioufas, Zisis},
  title = {The Role of Rho Kinase Inhibitors in Corneal Diseases},
  journal = {Drug Design, Development and Therapy},
  year = {2024},
  volume = {Volume 18},
  pages = {97--108},
  doi = {10.2147/dddt.s435522}
}
Kostenlos starten →